Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 6/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | CASP1 | P29466 | 2/20 | 0.54 |
| ▸ | CASP7 | P55210 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2524666 | 0.97 | CFTR (0.65) | CFTRALDH1A1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL14073369 | 0.87 | CFTR (0.70) | CFTRALDH1A1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL14235358 | 0.81 | CFTR (1.00) | CFTRALDH1A1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL12043197 | 0.75 | KDM4E (0.64) | ALDH1A1KMT2AKDM4ESMN1; SMN2MAPT | |
| SCHEMBL5016782 | 0.75 | KDM4E (0.73) | CFTRALDH1A1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL14235359 | 0.74 | CFTR (1.00) | CFTRALDH1A1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL14235249 | 0.74 | CFTR (1.00) | CFTRALDH1A1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL14235250 | 0.72 | CFTR (1.00) | CFTRALDH1A1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL14235251 | 0.71 | CFTR (1.00) | CFTRALDH1A1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL5016780 | 0.70 | KDM4E (0.71) | CFTRALDH1A1KMT2AKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039462-B2 | Alzheimer's disease, stroke, traumatic brain injury, and depression, neurodegenerative diseases; antidepressants; a phenyl thiourea or urea derivatives; promote cell proliferation of stem or progenitor cells | NEURONASCENT, INC. (US) | 2011-10-18 | — | — | US | disclosed |
| US-8039462-B2 | Alzheimer's disease, stroke, traumatic brain injury, and depression, neurodegenerative diseases; antidepressants; a phenyl thiourea or urea derivatives; promote cell proliferation of stem or progenitor cells | NEURONASCENT, INC. (US) | 2011-10-18 | — | — | US | disclosed |
| US-20080234253-A1 | Methods and Compositons for Stimulating Neurogenesis and Inhibiting Neuronal Degeneration | NEURONASCENT, INC. (US) | 2008-09-25 | — | — | US | disclosed |
| US-20080234253-A1 | Methods and Compositons for Stimulating Neurogenesis and Inhibiting Neuronal Degeneration | NEURONASCENT, INC. (US) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234253-A1 | Methods and Compositons for Stimulating Neurogenesis and Inhibiting Neuronal Degeneration | DCX, BDNF, GAP43 | CFTR 3437/4885ALDH1A1 1544/4885KMT2A 4557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.